rules that sales of generic versions of Hospira 's ( HSP -2.1% ) proprietary sedative ..... introduction of generic formulations. Hospira has filed an appeal of the decision and ..... version. Despite the adverse ruling, Hospira reaffirms its 2014 EPS guidance of $2
LONDON (Reuters) - U.S. drugmaker Hospira ’s HSP.N talks to buy the medical nutrition unit of Danone DANO.PA and use the deal to move its tax domicile abroad have
allow the sale of generic versions of Hospira 's ( HSP +1.4% ) sedative Precedex ..... injection) In its lawsuit filed yesterday, Hospira claims that the agency violated its own ..... intensive care unit sedation) covered by Hospira 's patent. In his order, Judge Jarrod
Aug 20 (Reuters) - A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.
Mylan ( MYL +1.3% ) launches dexmedetomidine hydrochoride injection, 100 mcg (base)/mL, the therapeutic equivalent of Hospira 's ( HSP -2.8% ) Precedex . The U.S. market is ~$156M. Mylan has 295 ANDAs pending FDA approval representing
(Adds details of Durbin letter, Wyden comment, background, byline)
WASHINGTON, Aug 14 (Reuters) - A senior U.S. senator said on Thursday he has written to the chief executive of Hospira Inc and urged the drug and medical device maker not to move its tax domicile...
infusion pump sales surging 40%; the company should continue to benefit from ongoing market share gains as competitors like Hospira struggle with regulatory issues. The company has also made progress in the installation of its Pyxis ES system, which led
plan to raise our fair value estimate for Hospira after the company reported strong second ..... product. We don’t plan any changes to Hospira ’s narrow economic moat, but the recent ..... Asia more than offset negative pricing on Hospira ’s European injectables. Management reported
Netherlands and brings 25 years of experience in the global pharmaceutical industry, which includes senior management roles in Hospira and Mayne Group. Our fair value estimate of AUD 2.50 per share and investment thesis remain intact pending the release of